Extinction of myeloproliferative neoplasm by acquisition of a lymphoid disease: JAK2V617F and JAK2 exon 12 allele burden disappearance during the follow-up of two patients

[1]  E. Rota,et al.  Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report , 2017, Journal of Medical Case Reports.

[2]  S. Hanada,et al.  Spontaneous regression of essential thrombocythemia with MPL mutation on menopause , 2014, International Journal of Hematology.

[3]  R. Hoffman,et al.  Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia. , 2014, Clinical lymphoma, myeloma & leukemia.

[4]  K. Shain,et al.  High-dose melphalan produces favorable response in a patient with multiple myeloma and coexisting essential thrombocythemia with JAK2 mutation , 2014, Bone Marrow Transplantation.

[5]  P. Shou,et al.  Interferon-α-secreting mesenchymal stem cells exert potent antitumor effect in vivo , 2014, Oncogene.

[6]  O. Mitrović,et al.  The emergence of non-secretory multiple myeloma during the non-cytotoxic treatment of essential thrombocythemia: a case report , 2013, Journal of Medical Case Reports.

[7]  B. Sriha,et al.  Multiple myeloma following essential thrombocythemia. , 2013, Annales de biologie clinique.

[8]  W. Kroes,et al.  No Evidence for JAK2V617F Mutation in Monoclonal B Cells in 2 Patients with Polycythaemia Vera and Concurrent Monoclonal B Cell Disorder , 2012, Acta Haematologica.

[9]  R. Foà,et al.  The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experience , 2011, American journal of hematology.

[10]  M. Griesshammer,et al.  Acquired thrombophilia in pregnancy: essential thrombocythemia. , 2003, Seminars in thrombosis and hemostasis.

[11]  A. Falus,et al.  ROLE OF INTERLEUKIN‐6 IN THE PATHOGENESIS OF MULTIPLE MYELOMA , 2000, Cell biology international.